All News
Filter News
Found 806,076 articles
-
FAU Appoints Safiya George, Ph.D. As Dean Of The Christine E. Lynn College Of Nursing
4/26/2019
Florida Atlantic University has named Safiya George, Ph.D., as the new dean of the Christine E. Lynn College of Nursing. She is only the third dean to be appointed in the college's 40-year history
-
SparingVision to Present Preclinical Datas for Retinitis Pigmentaria’s Treatment during Annual Congress of the Association for Research in Vision and Ophthalmology (ARVO)
4/26/2019
SparingVision, a biotechnology company focused on the discovering and development of an innovative, therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa (RP), announced that four communications (3 posters and 1 oral presentation) related to the SPVN06 gene therapy developed by SparingVision, will be presented during the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
-
AiRXOS Participates in Historic Unmanned Aircraft Delivery of Organ for Successful Transplant in Maryland
4/26/2019
AiRXOS, part of GE Aviation, participated in the world’s first unmanned aircraft (UA) flight that delivered a donor kidney to surgeons in Baltimore, Maryland for successful transplantation into a patient with kidney failure.
-
Alexion Receives Positive CHMP Opinion for ULTOMIRIS® (ravulizumab) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
4/26/2019
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization for ULTOMIRIS® (ravulizumab), the first and only long-acting C5 complement inhibitor administered every eight weeks.
-
Apex Health, Human Performance & Longevity Optimization is Helping Men Wave Goodbye to Erectile Dysfunction with Cutting-edge GAINSWave® Treatment
4/26/2019
Leah Hughes, APRN with Apex Health, Human Performance & Longevity Optimization is implementing a non-invasive and drug-free solution for Erectile Dysfunction (ED).
-
FDA approves device to help increase access to more lungs for transplant
4/26/2019
The U.S. Food and Drug Administration approved a device, called Xvivo Perfusion System with Steen Solution Perfusate, that can temporarily ventilate, oxygenate, and pump preservation solution through lungs that were initially thought to be unacceptable for transplant.
-
AVROBIO Highlights the plato™ Platform and Gaucher and Cystinosis Programs at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy
4/26/2019
AVROBIO, Inc. announced the participation of its senior management in sessions at the Annual Meeting of the American Society of Gene and Cell Therapy.
-
CRH Medical Corporation to Present at the Bloom Burton & Co. Healthcare Investor Conference
4/26/2019
CRH Medical Corporation, announces that it will participate in the Bloom Burton & Co. Healthcare Investor Conference 2019 at the Metro Toronto Convention Center in Toronto, Ontario.
-
McKesson Appoints Tracy Faber to Top HR Role
4/26/2019
McKesson Corporation announced that Tracy Faber has been appointed executive vice president and chief human resources officer (CHRO), effective October 1, 2019. Faber will report to CEO Brian Tyler.
-
NeurExo Sciences and Henry Ford Health System Present Preclinical Data on Exosomes at ISEV2019 Annual Meeting
4/26/2019
Exosomes demonstrate ability to enhance anti-tumor effect of platinum-based drugs and to ameliorate peripheral neuropathy
-
Mylan to Release First Quarter 2019 Financial Results on May 7, 2019
4/26/2019
Global pharmaceutical company Mylan N.V. announced that it will release its first quarter 2019 financial results on Tues., May 7, before the open of the U.S. financial markets.
-
Adaptive Biotechnologies Appoints Lance Baldo, M.D., as Chief Medical Officer
4/26/2019
Adaptive Biotechnologies announced the appointment of Lance Baldo, M.D., as Chief Medical Officer.
-
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 26, 2019
4/26/2019
Audentes Therapeutics, Inc. announced it has granted equity awards on April 24, 2019, that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to nine individuals hired by Audentes from April 2 through April 24, 2019.
-
New Scientific And Clinical Analyses Regarding Bausch + Lomb Surgical And Pharmaceutical Products To Be Presented During The Association For Research In Vision And Ophthalmology Meeting
4/26/2019
Data from the Company's Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) Study will also be Featured
-
BioPharmX Completes 1-for-25 Reverse Stock Split
4/26/2019
BioPharmX Corporation announces the completion of the reverse stock split previously announced on April 15, 2019 to regain compliance with certain NYSE American continued listing standards related to the low price per share of the Company's common stock.
-
Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER
4/26/2019
First-quarter sales(2) growth driven by Specialty Care, Vaccines and strong contribution from Emerging Markets
-
Boston Scientific Corp. Shareholder Alert: Securities Lawsuit Filed Against BSX
4/26/2019
Thornton Law Firm LLP announces that it is investigating a securities class action on behalf of shareholders and investors who purchased the securities of Boston Scientific Corporation.
-
Navidea Biopharmaceuticals Announces Comparative Study to Evaluate the Potential Utility of Tilmanocept In Patients with Tuberculosis (“TB”)
4/26/2019
New comparative study of 68Ga-Tilmanocept and 18F-FDG PET/CT in the evaluation of patients with TB
-
BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy and Repair Conference
4/26/2019
BioTime, Inc. announced that Edward D. Wirth, III, M.D., Ph.D., Chief Medical Officer of BioTime, will present at the 26th Annual American Society for Neural Therapy and Repair (ASNTR) Annual Conference on April 26th, 2019 at 10:30am EDT as part of Session 6: “Spinal Cord Injury”.
-
J. David Warren, Ph.D., Joins Scientific Advisory Board of Akelos Inc., Biotechnology Company Developing Opioid Alternatives
4/26/2019
Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain, adds J. David Warren, Ph.D., to its Scientific Advisory Board.